Alzheimer’s Research UK has announced a Drug Discovery Alliance, which will see research centres pooling their expertise to fight the disease.
These drug discovery institutes will be at Cambridge and Oxford Universities and University College London.
The Drug Discovery Institutes will see about 90 new research scientists, recruited over the next five years, employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.
The last treatment for dementia was licensed in the UK 12 years ago.
At the G8 Dementia Summit a year ago, health leaders from across the world pledged a research ambition for a disease-modifying therapy for dementia by 2025.
Alzheimer’s Research UK says that with one dementia researcher for every six working on cancer, attracting new expertise to tackle the growing global health problem is crucial.
Dr Eric Karran, director of research at the charity, said: “Working in universities and hospitals alongside people affected by dementia and their families, academic researchers are best placed to take research breakthroughs and progress them into real world benefits for the people that so desperately need them.
“The Drug Discovery Alliance is one of the first of its kind for dementia research in the world.
“We’re providing the investment and infrastructure that is needed to maintain and grow a healthy pipeline of potential new treatments to take forward into clinical testing.”
Health Secretary Jeremy Hunt, said: “Dementia can be a devastating condition and I am committed to doing all that we can to help the thousands of people who live with it.
“These world-leading Institutes will bring new hope to people with dementia by boosting innovation and increasing collaboration so that we can achieve our aim of finding a cure or disease-modifying therapy.”